HRGN (Harvard Apparatus Regenerative Technology) Beta: -0.0969 (As of Jun. 26, 2026)


HRGN Harvard Apparatus Regenerative Technology Inc HRGN
34 GF Score
Price $1.39
GF Value $5.34
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology Beta?

Harvard Apparatus Regenerative Technology HRGN 34 Beta is -0.0969 as of Jun. 26, 2026. GuruFocus rates HRGN with a GF Score™ of 34/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Harvard Apparatus Regenerative Technology's Beta is -0.0969.


Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Harvard Apparatus Regenerative Technology Beta Related Terms


Harvard Apparatus Regenerative Technology Beta Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology Beta Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.62 -1.24 -0.68 -0.80 0.22

Harvard Apparatus Regenerative Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.00 0.38 0.22 0.23

HRGN vs DTEAF, WYGC, BFNH: Beta Comparison

For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology Beta vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Beta distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Beta falls into.


HRGN
34GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Apparatus Regenerative Technology Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0969 mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Beta of -0.0969 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Harvard Apparatus Regenerative Technology and its competitors.
Is Harvard Apparatus Regenerative Technology's Beta too high?
Harvard Apparatus Regenerative Technology's current Beta is -0.0969. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Beta compare to DTEAF and WYGC?
Harvard Apparatus Regenerative Technology's Beta of -0.0969 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Consumer Packaged Goods company?
A good Beta depends on the Consumer Packaged Goods industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Harvard Apparatus Regenerative Technology and its competitors. Harvard Apparatus Regenerative Technology's current Beta is -0.0969. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current Beta is -0.0969. Harvard Apparatus Regenerative Technology's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Beta is -0.0969 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

  • Beta: -0.0969
  • GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
  • GF Score™: 34/100 with 2 warning signs

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
34GF Score

Get the complete analysis for HRGN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$5.34
GF Value